M Koninckx1, J L Marco2, I Pérez2, M T Faus2, V Alcolea3, F Gómez4. 1. Department of Hospital Pharmacy, Francesc de Borja Hospital of Gandia, Valencia, Spain. koninchk_man@gva.es. 2. Department of Hospital Pharmacy, Francesc de Borja Hospital of Gandia, Valencia, Spain. 3. Department of Medical Oncology, Francesc de Borja Hospital of Gandia, Valencia, Spain. 4. Department of Preventive Medicine, Arnau de Vilanova Hospital, Valencia, Spain.
Abstract
PURPOSE: New therapies with diverse mechanisms of action are available for metastatic castration-resistant prostate cancer (mCRPC). This study aims to evaluate the effectiveness, safety and cost of abiraterone acetate (AA) in patients with mCRPC. MATERIALS AND METHODS: Observational retrospective cohort study in which mCRPC patients who initiated AA between January 1, 2012 and December 31, 2017, were included. The patients were followed-up until death or March 31, 2018. Demographic, clinical and economic data were collected from the corporate electronic information systems. Survival distributions were estimated using the Kaplan-Meier method and compared using the log-rank test. RESULTS: A total of 69 mCRPC patients were started on AA, of whom 18 (26.1%) received prior chemotherapy (post-CT) and 51 (73.9%) did not receive it (CT-naïve). A PSA decline of ≥ 50% was achieved in five (27.8%) post-CT and 32 (62.7%) CT-naïve patients (p = 0.011). Median time to PSA progression, progression-free survival (PFS) and overall survival (OS) were 4.4/7.9 months (p = 0.003), 5.1/7.5 months (p = 0.034) and 12.1/21.3 months (p = 0.119), respectively, for post-CT/CT-naïve patients. Treatment-related adverse events (AEs) occurred in 10 (55.6%) post-CT and 11 (21.6%) CT-naïve patients (p = 0.007). The most common AEs were hypokalaemia (11.6%), hypertension (8.7%) and fatigue (5.8%). The cost per median PFS month and per median OS month was €2818.4/€2784.3 and €1187.9/€980.4 for post-CT/CT-naïve patients, respectively. CONCLUSIONS: CT-naïve patients treated with AA obtained a better clinical benefit in terms of effectiveness, safety and cost-effectiveness ratio than post-CT patients. The effectiveness outcomes were poorer than those reported previously in the clinical trial setting.
PURPOSE: New therapies with diverse mechanisms of action are available for metastatic castration-resistant prostate cancer (mCRPC). This study aims to evaluate the effectiveness, safety and cost of abiraterone acetate (AA) in patients with mCRPC. MATERIALS AND METHODS: Observational retrospective cohort study in which mCRPC patients who initiated AA between January 1, 2012 and December 31, 2017, were included. The patients were followed-up until death or March 31, 2018. Demographic, clinical and economic data were collected from the corporate electronic information systems. Survival distributions were estimated using the Kaplan-Meier method and compared using the log-rank test. RESULTS: A total of 69 mCRPC patients were started on AA, of whom 18 (26.1%) received prior chemotherapy (post-CT) and 51 (73.9%) did not receive it (CT-naïve). A PSA decline of ≥ 50% was achieved in five (27.8%) post-CT and 32 (62.7%) CT-naïve patients (p = 0.011). Median time to PSA progression, progression-free survival (PFS) and overall survival (OS) were 4.4/7.9 months (p = 0.003), 5.1/7.5 months (p = 0.034) and 12.1/21.3 months (p = 0.119), respectively, for post-CT/CT-naïve patients. Treatment-related adverse events (AEs) occurred in 10 (55.6%) post-CT and 11 (21.6%) CT-naïve patients (p = 0.007). The most common AEs were hypokalaemia (11.6%), hypertension (8.7%) and fatigue (5.8%). The cost per median PFS month and per median OS month was €2818.4/€2784.3 and €1187.9/€980.4 for post-CT/CT-naïve patients, respectively. CONCLUSIONS:CT-naïve patients treated with AA obtained a better clinical benefit in terms of effectiveness, safety and cost-effectiveness ratio than post-CTpatients. The effectiveness outcomes were poorer than those reported previously in the clinical trial setting.
Authors: Philip Cornford; Joaquim Bellmunt; Michel Bolla; Erik Briers; Maria De Santis; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Nicolas Mottet Journal: Eur Urol Date: 2016-08-31 Impact factor: 20.096
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Luca Cindolo; Clara Natoli; Cosimo De Nunzio; Michele De Tursi; Maurizio Valeriani; Silvana Giacinti; Salvatore Micali; Mino Rizzo; Giampaolo Bianchi; Eugenio Martorana; Marcello Scarcia; Giuseppe Mario Ludovico; Pierluigi Bove; Anastasia Laudisi; Oscar Selvaggio; Giuseppe Carrieri; Maida Bada; Pietro Castellan; Stefano Boccasile; Pasquale Ditonno; Paolo Chiodini; Paolo Verze; Vincenzo Mirone; Luigi Schips Journal: BMC Cancer Date: 2017-11-10 Impact factor: 4.430
Authors: Oliver E Yausep; Raksheeth Agarwal; Rifqha Aulina; Anthony E Wijaya; Ilonka Amaia; Addina W Moekti; Ikhwan Rinaldi; Agus Rizal A H Hamid Journal: Clin Case Rep Date: 2019-07-11
Authors: G Procopio; V E Chiuri; M Giordano; A R Alitto; R Maisano; R Bordonaro; S Cinieri; S Rossetti; S De Placido; M Airoldi; L Galli; D Gasparro; G M Ludovico; P F Guglielmini; C Carella; P Nova; M Aglietta; L Schips; P Beccaglia; A Sciarra; L Livi; D Santini Journal: ESMO Open Date: 2022-04-08